Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Barriers towards the publication of academic drug trials. Follow-up of trials approved by the Danish Medicines Agency.

Berendt L, Petersen LG, Bach KF, Poulsen HE, Dalhoff K.

PLoS One. 2017 May 9;12(5):e0172581. doi: 10.1371/journal.pone.0172581. eCollection 2017.

2.

A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science: Workshop Proceedings and Commentary.

Borup G, Bach KF, Schmiegelow M, Wallach-Kildemoes H, Bjerrum OJ, Westergaard N.

Ther Innov Regul Sci. 2016 May;50(3):304-311. doi: 10.1177/2168479015622668.

PMID:
30227074
3.

From protocol to published report: a study of consistency in the reporting of academic drug trials.

Berendt L, Callréus T, Petersen LG, Bach KF, Poulsen HE, Dalhoff K.

Trials. 2016 Feb 19;17:100. doi: 10.1186/s13063-016-1189-4.

4.

Innovation of Medical Products: The Evolution of Regulatory Science, Research, and Education.

Spindler P, Bach KF, Schmiegelow M, Bedlington N, Eichler HG.

Ther Innov Regul Sci. 2016 Jan;50(1):44-48. doi: 10.1177/2168479015599810.

PMID:
30236007
5.

[Simplification of procedures for clinical drug trials in the EU is coming up].

Bach KF, Jørgensen A.

Ugeskr Laeger. 2013 Nov 11;175(46):2778-81. Review. Danish.

PMID:
24629314
6.

[Empty cardboard boxes and lobbyism].

Bach KF.

Ugeskr Laeger. 2011 Jan 10;173(2):105. Danish. No abstract available.

PMID:
21219839
7.

Methodological characteristics of academic clinical drug trials--a retrospective cohort study of applications to the Danish Medicines Agency 1993-2005.

Berendt L, Håkansson C, Bach KF, Andreasen PB, Petersen LG, Andersen E, Poulsen HE, Dalhoff K.

Br J Clin Pharmacol. 2010 Nov;70(5):729-35. doi: 10.1111/j.1365-2125.2010.03755.x.

8.

[How to achieve an easier way to clinical research?].

Bach KF.

Ugeskr Laeger. 2010 Apr 12;172(15):1154. Danish. No abstract available.

PMID:
20429150
9.

[Effect of the GCP Directive on academic drug trials].

Berendt L, Håkansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, Andersen E, Poulsen HE.

Ugeskr Laeger. 2008 Aug 11;170(33):2437-9. Danish.

PMID:
18761825
10.

Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006.

Berendt L, Håkansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, Andersen E, Poulsen HE.

BMJ. 2008 Jan 5;336(7634):33-5. Epub 2007 Dec 6.

11.

[What is necessary to archive when one writes a case report?].

Bjarnason NH, Bach KF.

Ugeskr Laeger. 2006 Jan 3;168(1):78-9. Danish. No abstract available.

PMID:
16393578
12.

[New regulations on drug research].

Bach KF, Friis K, Jørgensen A.

Ugeskr Laeger. 2004 Apr 26;166(18):1657-9. Danish. No abstract available.

PMID:
15174399
13.

[Is good clinical practice a problem?].

Bach KF, Friis K, Jørgensen A.

Ugeskr Laeger. 2004 Apr 26;166(18):1649. Danish. No abstract available.

PMID:
15174396
14.

Good clinical practice is now obligatory in academic clinical drug research in the European Union.

Jørgensen A, Bach KF, Friis K.

Basic Clin Pharmacol Toxicol. 2004 Feb;94(2):57-8.

15.

Medication history on internal medicine wards: assessment of extra information collected from second drug interviews and GP lists.

Andersen SE, Pedersen AB, Bach KF.

Pharmacoepidemiol Drug Saf. 2003 Sep;12(6):491-8.

PMID:
14513663
16.

[Osteoarthritis].

Unkerskov J, Glintborg D, Bach KF, Kampmann JP.

Ugeskr Laeger. 2002 Aug 12;164(33):3875; author reply 3875-6. Danish. No abstract available.

PMID:
12216164
17.

[Can drugs reduce the need for blood transfusion in the course of surgery?].

Bach KF, Kjoergaard J, Christensen HR.

Ugeskr Laeger. 1999 Jan 25;161(4):457-8. Danish. No abstract available.

PMID:
9951371

Supplemental Content

Loading ...
Support Center